TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old with informed consent~2. Histologically (preferred) or radiologically confirmed distal malignant bile duct tumors~3. Inoperability by staging, comorbidities or patient wishes~4. Distal tumors 2cm away from the portal hilum~5. Bilirubin \> 50umol/L at diagnosis~Exclusion Criteria:~1. Periampullary tumours~2. Multiple hepatic metastases with significant blockage of one or more liver segments (if no segment blockage, metastasis is not an exclusion criteria)~3. Presence of main portal vein thrombosis~4. Prior SEMS placement~5. Prior Billroth II or roux-en Y reconstruction~6. History of bleeding disorder or use of anticoagulation~7. Child's B/C cirrhosis~8. Pregnancy~9. Performance status ECOG ≥3 (confined to bed / chair \> 50% waking hours)~10. Presence of other malignancy~11. Presence of gastric outlet obstruction~12. Life expectancy \< 3months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEMS only (Type: ACTIVE_COMPARATOR): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
- EBRFA and SEMS (Type: ACTIVE_COMPARATOR): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Age ≥ 18 years~* Breast cancer patients suffering from chemotherapy-induced peripheral neuropathy for at least 3 months after the end of their last cancer chemotherapy~* Numerical rating scale ≥ 4~* Patient in stable clinical situation on the next month (no surgery, radiotherapy, hormone therapy, chemotherapy or other treatment scheduled in the month following the enrollment)~* Patients affiliated to the French Social Security~* Patients with free and informed consent has been obtained~Exclusion Criteria:~* - Hypersensitivity to the active substance or to any of the excipients~* Hypertension~* History of stroke~* Severe heart failure~* Severe hepatic impairment~* Shortness of breath~* Congenital galactosemia, glucose-galactose malabsorption, lactase deficiency~* Association with linezolid~* Pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy~* Diabetes (type I and II)~* Medical and surgical history incompatible with the study~* Patient receiving treatment with amantadine, ketamine, memantine, L-Dopa, dopaminergic agonists, anticholinergics, barbiturates, neuroleptics, Monoamine oxidase inhibitor, dantrolene or baclofen, phenytoin, cimetidine, ranitidine, procainamide, quinidine, quinine, amiodarone, fluoxetine, paroxetine, propafenone, thioridazine, ritonavir, nicotine, hydrochlorothiazide, warfarin~* Present or past psychotropic substances and alcohol dependence~* Childbearing age, no use of effective contraceptive method, pregnancy or lactation~* Patient exclusion period, or the total allowable compensation exceeded~* Patients undergoing a measure of legal protection (guardianship, supervision ...)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dextromethorphan (Type: EXPERIMENTAL): The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
- placebo (Type: PLACEBO_COMPARATOR): The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Understanding Hemophilia A and B Drug Dosage Administration Patterns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Physician/Clinician Participants:~* Must be a healthcare provider~* Currently manages at least 10 hemophilia A and/or B patients~Patient Participants:~* Willing and able to provide informed consent~* Diagnosed with hemophilia A or B~* Current disease severity is either moderately severe or severe with a clotting factor level of ≤5%~* If suffering from hemophilia A, must be currently taking moroctocog alfa (or another standard half-life treatment), rurioctocog alfa or efraloctocog alfa for at least six months.~(If currently taking rurioctocog alfa or efraloctocog alfa, must have been switched from a standard half-life treatment and had been on that prior treatment for at least six months).~* If suffering from hemophilia B, must be currently taking nonacog alfa or eftrenonacog alfa for at least six months (If currently taking eftrenonacog alfa, must have switched from nonacog alfa and had been on that prior treatment for at least six months).~* Infuse at least 3 times per month~Exclusion criteria:~* Female with hemophilia A or B~* Mild Haemophilia A or B

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemophilia B (Type: None): real world administration patterns and resource utilization implications
- Hemophilia A (Type: None): real world administration patterns and resource utilization implications

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Long Term, High Intensity and Long Time Stretch Training Program on Viscoelasticity Plantarflexors Muscle in Children With Cerebral Palsy (CP).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 8 to 16 years~* Children diagnosed spastic cerebral palsy~* Children with decrease maximal dorsiflexion angle under +5° in the last four weeks~* Children who don't understand instructions~Exclusion Criteria:~* Children who had damage orthopedics or surgical operation contraindicating realization of the experimental protocol~* Hospitalization incompatible with the progress of the protocol.~* Children who had botulinum injection, extensions casts or the implementation of new equipment (night or day orthosis) for less than three months or the progress of the protocol.~* Children having analgesic treatment in progress

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Children with spastic cerebral palsy (Type: EXPERIMENTAL): Children with spastic cerebral palsy will be included. They will have 3 phases:~* Baseline: 4, 5 or 6 evaluations~* Intervention: 9 evaluations before and after every stretching session~* Follow-up: 4, 5 or 6 evaluations~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Metformin as an Upstream Therapy in Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All individuals diagnosed with Atrial Fibrillation and choosing to undergo a rhythm control strategy at Robert Packer Hospital with a BMI ≥ 27 will be eligible for the study. All subjects must be able to understand and willing to sign a written informed consent document.~Exclusion Criteria:~* Individuals who are already taking metformin or other antidiabetic medications including insulin, have a diagnosis of diabetes, have a known allergy or FDA-labeled contraindication to taking metformin, eGFR below 30 mL/min per 1.73 m2 or other clinical diagnosis of advanced renal disease,, have acute or chronic metabolic acidosis (serum bicarbonate \<22 mEq/L), have a history of significant alcohol use (\>2 drinks/day on average), have a history of hepatic dysfunction (serum bilirubin 1.5X greater than the upper limit of normal), have a history of New York Heart Association (NYHA) Class III or IV heart failure, or are pregnant will be excluded from the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin Group (Type: EXPERIMENTAL): Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
- Control Group (Type: NO_INTERVENTION): Standard of care - ablation only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise in Adolescents With Insulin Resistance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12-18 years inclusive~* Typically developing and cognitively intact~Exclusion Criteria:~* Diabetes (≥126 mg dL-1 fasting glucose)~* Insulin treatment or sensitizing drugs~* Diagnosis of kidney, pulmonary, or heart disease (an asthma diagnosis that is not currently being treated with a daily controller medicine or asthma that requires medication use prior to exercise is not considered a pulmonary disease)~* Current smoking (defined as use of nicotine \>5 times in the past month)~* Pregnancy~* Neurological or developmental disorders (e.g., intellectual disability, autism)~* Significant head injury or medical conditions (e.g., concussion, encephalopathy, seizure disorder)~* Inability to undergo the MRI procedure~* Weight less than 94.5 lbs (42.9 kg) to adhere to safety guidelines regarding blood sampling and OGTT administration~* Tanner Stage \<3~* Any other circumstance deemed by the PI not addressed above

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Enrolled, eligible (Type: EXPERIMENTAL): Single arm for eligible subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DXA Precision and Accuracy Comparison Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women \> 20 years old~2. Willing to provide consent~3. Falls into one of three weight categories, with minimum 30 subjects per category.~   * Less than 200 lbs.~  * 200 (inclusive) to less than 350 lbs.~  * 350 (inclusive) to less than 450 lbs.~4. Participate in only one weight category in either skeletal or body composition cohort, or both.~Exclusion Criteria:~1. Inability to remain still for the duration of the DXA scans as judged by study Investigator.~2. Un-removable internal / external scan artifacts e.g. plaster casts, metal rodding naso-gastric tubes, etc.~3. Females of childbearing potential\* with actual (confirmed by positive urine pregnancy test) or suspected (based on study Investigator evaluation despite a negative urine test) pregnancy.~4. Subject had already given consent to participate in any aspect of this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Skeletal (Type: EXPERIMENTAL): Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\], and 60 will be measured on all three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\],(total of evaluable 90 subjects).~\*\* Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.\*\*
- Body Composition (Type: EXPERIMENTAL): Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\], and 60 will be measured on all three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\], (total of evaluable 90 subjects).~\*\* Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.\*\*
- Skeletal & Body Composition (Type: EXPERIMENTAL): Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems \[Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)\]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* colorectal metastatic adenocarcinoma (stage IV) with unresectables, measurables and visibles secondary lesions~* primitive tumor must be operate~* patient age between 18 and 70~* OMS status performance \< 2~* life expectancy \> 12 weeks~* hematologic function : PNN \>/= 1.5x10\^9/L, platelets \>/= 100x10\^9/L~* hepatic function : bilirubin \</= 1.5xLSN, AST and ALT \</= 3xLSN, alcalin phosphatasis \</= 3xLSN~* plasmatimic creatin \</= 1.25xLSN~* No previous chemotherapy or pelvic radiotherapy~* men and women in age of procreate agreeing to use a contraception until 4 months after the end of treatment for women and until 6 months for men~Exclusion Criteria:~* nonmetastatic forms~* Colorectal tumor which requires preoperative radiotherapy~* nonmeasurable metastasis based on RECIST criteria~* previous chemotherapy for colorectal cancer~* previous irradiation of the primitive tumour~* specific indication against the treatment studied~* Patient considered as inoperable for physiological or carcinologic reasons~* Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOX + surgery + FOLFOX (Type: EXPERIMENTAL): * Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~* resection of the colorectal tumor during surgery~* Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ESP vs QL for Total Abdominal Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female ASA physical status 1-3 scheduled for open abdominal hysterectomy~* Age 18-80 years old~* Able to participate personally or by legal representative in informed consent in English or Spanish~Exclusion Criteria:~* History of relevant drug allergy~* Age less than 18 or greater than 80 years~* Chronic opioid use or drug abuse~* Active use of anticoagulant medication~* Significant psychiatric disturbance~* Inability to understand the study protocol~* Refusal to provide written consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound-guided ESP block with liposomal bupivacaine (Type: EXPERIMENTAL): For the ESP block, the transducer will be placed parasagittally at the level of the tip of the scapula and the anesthesiologist will scan in a craniocaudal manner to identify the ipsilateral T10 transverse process and overlying erector spinae muscle. Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the muscle and transverse process. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.
- Ultrasound-guided QL block with liposomal bupivacaine (Type: ACTIVE_COMPARATOR): For the QL block, the transducer will be placed transversely over the lumbar spine at the level of the iliac crest. Then, the anesthesiologist will scan laterally to identify the ipsilateral L3 transverse process, psoas muscle, and quadratus lumborum muscle to identify the Shamrock Sign (7). Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the quadratus lumborum muscle and psoas muscle. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the two muscles. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Oral Lichen Planus~* Oral Erosive Area More Than 1cm²~* Lichen Planus Pathologically Proven~Exclusion Criteria:~* No Previous Treatment by Rapamycin~* Non Child Bearing Or Breast Feeding Woman~* Patient Who Cannot Be Treated By Rapamycin Or Betamethasone~* Chronic Renal Insufficiency (Creatinin Clearance \< 40ml/Mn)~* Ongoing Treatment By Topical Calcineurin Inhibitors Or Systemic Steroids Or Retinoids Or Systemic Immunosuppressors Or Thalidomide Or Griseofulvin Or Antimalarials~* Cholesterolemia \>7.8 Mmol/L Or Hypertriglyceridemia \>3.95mmol/L Non Responsive To Medical Treatments~* Leucopenia (\<3000/Mm3)~* Thrombopenia (\<100 000/Mm3)~* Hypertransaminasemia (\>3n)~* Hypersensitivity To Macrolides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- T (Type: EXPERIMENTAL): TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
- C (Type: ACTIVE_COMPARATOR): TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues